Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event"Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy” Featuring GeoVax CEO David Dodd on May 28, 2026
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar EventSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW!A number of actively traded small-cap and growth stocks are drawing increased investor attention as momentum continues building across sectors tied to AI infrastructure, biotechnology, GLP-1 healthcare, vaccines, high-performance computing, and digital infrastructure. Names currently trading actively include ENDRA Life Sciences Inc. (
NASDAQ: NDRA), Sunshine Biopharma Inc. (
NASDAQ: SBFM), GeoVax Labs Inc. (
NASDAQ: GOVX), HIVE Digital Technologies Ltd. (
NASDAQ: HIVE), and Sphere 3D Corp. (
NASDAQ: ANY).
ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor AwarenessENDRA Life Sciences Inc. (
NASDAQ: NDRA) is gaining increasing investor attention as the company advances its TAEUS® Liver imaging platform while simultaneously evaluating strategic alternatives aimed at maximizing shareholder value.
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)Company Aligns Resources With Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine PlatformsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine PlatformsCompany Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease ThreatsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease ThreatsWHO Emergency Declaration of Ebola Outbreak and Ongoing Mpox Developments Reinforce the Importance of Diversified Vaccine Supply and Scalable U.S.-Based Manufacturing Capabilities
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq RulesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq RulesATLANTA, GA - May 18, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has entered into a securities purchase agreement with existing institutional investors for the purchase and sale of 2,027,027 shares of common stock (or common stock equivalents in lieu thereof) together with (i) Series A warrants to purchase up to 2,027,027 shares of common stock with an exercise price of $1.48 per share and a five-year term, and (ii) Series B warrants to purchase up to 2,027,027 shares of common stock with an exercise price of $1.48 per share and an 18-month term, for aggregate gross proceeds of approximately $3 million, before deducting placement agent fees and other offering expenses.
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation PlansSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation PlansATLANTA, GA - May 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today reported financial results for the quarter ended March 31, 2026, and provided a business update highlighting continued advancement of GEO-MVA, the Company’s Modified Vaccinia Ankara (MVA) vaccine candidate for mpox and smallpox, together with strategic progress in its immuno-oncology initiatives centered on Gedeptin®.
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold TumorsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold TumorsCompany Expands Strategic Immuno-Oncology Positioning Around Tumor Microenvironment Modulation, Checkpoint Enhancement, and Multi-Tumor Development Potential
GeoVax Announces a Warrant Inducement TransactionSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces a Warrant Inducement TransactionATLANTA, GA - May 7, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with existing institutional investors of the Company for the immediate exercise of existing warrants (the "Existing Warrants") to purchase up to 501,144 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) for gross cash proceeds of approximately $595,000, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging PathwaySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging PathwayCompany Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership OpportunitiesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership OpportunitiesNear-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer TherapiesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports 2025 Year-End Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
